Latest Regulatory News

Vital Metals Limited has had its trading suspension lifted following announcements addressing an ASX Price and Volume Query and a new capital raise, signaling renewed market activity.

Meteoric Resources confirms its Caldeira Rare Earth Project in Brazil remains on track after a disputed environmental council vote was declared invalid. Strong local government support and regulatory assurances underpin confidence in project timelines.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Karoon Energy has upgraded its 2025 production guidance even as a key downhole pump failure at its Baúna Project in Brazil restricts output. The company is planning a rig-based intervention to restore full capacity by mid-2026.

Dome Gold Mines has announced a $5 million Share Purchase Plan at a 6.25% discount to fund critical milestones for its Sigatoka Sands Project in Fiji, aiming to secure a mining licence and commence operations.

GR Engineering Services Limited has announced a fully franked ordinary dividend of AUD 0.12 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 2.5% discount.

Platinum Asia Investments Limited has finalized its special dividend payment, confirming an amount of AUD 0.2011 per share with a high franking percentage. The dividend is set for payment in September following court approval of its scheme of arrangement.

MRG Metals Limited has seen its MRQOD securities suspended from ASX trading pending regulatory compliance, raising questions about the company’s next steps.

American West Metals has completed critical development and permitting milestones at its Storm Copper Project in Nunavut, Canada, advancing its Pre-Feasibility Study and revealing promising drilling results that hint at resource expansion.

Strickland Metals has completed the distribution of Gateway Mining shares to its shareholders following the sale of its Yandal Project, marking a significant step in its corporate restructuring.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.